Blocking epidermal growth factor receptor activation by 3,3′-diindolylmethane suppresses ovarian tumor growth in vitro and in vivo

Journal of Pharmacology and Experimental Therapeutics

Volumn 341, Issue 1, 2012, Pages 24-32

  Kandala, Prabodh K ^a   Wright, Stephen E ^a   Srivastava, Sanjay K ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,3' DIINDOLYLMETHANE; CASPASE 3; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; TRANSCRIPTION FACTOR ELK 1; TYROSINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; M PHASE CELL CYCLE CHECKPOINT; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; FEMALE; HUMANS; INDOLES; MICE; MICE, NUDE; OVARIAN NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84858658094     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.188706     Document Type: Article

References (40)

1. Ahmed N, Pansino F, Baker M, Rice G, and Quinn M (2002) Association between alphavbeta6 integrin expression, elevated p42/44 kDa MAPK, and plasminogen-dependent matrix degradation in ovarian cancer. J Cell Biochem 84:675-686. (Pubitemid 34113107)
2. Ali S, Banerjee S, Ahmad A, El-Rayes BF, Philip PA, and Sarkar FH (2008) Apoptosis-inducing effect of erlotinib is potentiated by 3,3′- diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer. Mol Cancer Ther 7:1708-1719.
3. Alper O, Bergmann-Leitner ES, Bennett TA, Hacker NF, Stromberg K, and Stetler-Stevenson WG (2001) Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. J Natl Cancer Inst 93:1375-1384. (Pubitemid 32936814)
4. Barrena Medel NI, Wright JD, and Herzog TJ (2010) Targeted therapies in epithelial ovarian cancer. J Oncol 2010:314326.
5. Bast RC Jr, Hennessy B, and Mills GB (2009) The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 9:415-428.
6. Bier E (1998) Localized activation of RTK/MAPK pathways during Drosophila development. Bioessays 20:189-194.
7. Boreddy SR, Pramanik KC, and Srivastava SK (2011) Pancreatic tumor suppression by benzyl isothiocyanate is associated with inhibition of PI3K/AKT/FOXO pathway. Clin Cancer Res 17:1784-1795.
8. Casanova ML, Larcher F, Casanova B, Murillas R, Fernández- Aceñero MJ, Villanueva C, Martínez-Palacio J, Ullrich A, Conti CJ, and Jorcano JL (2002) A critical role for ras-mediated, epidermal growth factor receptor-dependent angiogenesis in mouse skin carcinogenesis. Cancer Res 62:3402-3407. (Pubitemid 34651386)
9. Ciska E, Verkerk R, and Honke J (2009) Effect of boiling on the content of ascorbigen, indole-3-carbinol, indole-3-acetonitrile, and 3,3′-diindolylmethane in fermented cabbage. J Agric Food Chem 57:2334-2338.
10. Cowley S, Paterson H, Kemp P, and Marshall CJ (1994) Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 77:841-852. (Pubitemid 24187682)
11. Crews CM, Alessandrini A, and Erikson RL (1992) The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. Science 258:478-480.
12. Del Priore G, Gudipudi DK, Montemarano N, Restivo AM, Malanowska-Stega J, and Arslan AA (2010) Oral diindolylmethane (DIM): pilot evaluation of a nonsurgical treatment for cervical dysplasia. Gynecol Oncol 116:464-467.
13. Grose KR and Bjeldanes LF (1992) Oligomerization of indole-3-carbinol in aqueous acid. Chem Res Toxicol 5:188-193.
14. Hall JP and Davis RJ (2002) Inhibition of the p38 pathway upregulates macrophage JNK and ERK activities, and the ERK, JNK, and p38 MAP kinase pathways are reprogrammed during differentiation of the murine myeloid M1 cell line. J Cell Biochem 86:1-11. (Pubitemid 34595007)
15. Heath EI, Heilbrun LK, Li J, Vaishampayan U, Harper F, Pemberton P, and Sarkar FH (2010) A phase I dose-escalation study of oral BR-DIM (BioResponse 3,3′-Diindolylmethane) in castrate-resistant, non-metastatic prostate cancer. Am J Transl Res 2:402-411.
16. Jang K, Kim M, Seo HS, and Shin I (2010) PTEN sensitizes MDA-MB-468 cells to inhibition of MEK/Erk signaling for the blockade of cell proliferation. Oncol Rep 24:787-793.
17. Jemal A, Bray F, Center MM, Ferlay J, Ward E, and Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69-90.
18. Kandala PK and Srivastava SK (2010) Activation of checkpoint kinase 2 by 3,3′-diindolylmethane is required for causing G2/M cell cycle arrest in human ovarian cancer cells. Mol Pharmacol 78:297-309.
19. Kohler M, Janz I, Wintzer HO, Wagner E, and Bauknecht T (1989) The expression of EGF receptors, EGF-like factors and c-myc in ovarian and cervical carcinomas and their potential clinical significance. Anticancer Res 9:1537-1547.
20. Leung PC and Choi JH (2007) Endocrine signaling in ovarian surface epithelium and cancer. Hum Reprod Update 13:143-162. (Pubitemid 46323192)
21. Li Y, Chinni SR, and Sarkar FH (2005) Selective growth regulatory and proapoptotic effects of DIM is mediated by AKT and NF-kappaB pathways in prostate cancer cells. Front Biosci 10:236-243. (Pubitemid 40543031)
22. Nishioka C, Ikezoe T, Yang J, Takeshita A, Taniguchi A, Komatsu N, Togitani K, Koeffler HP, and Yokoyama A (2008) Blockade of MEK/ERK signaling enhances sunitinib-induced growth inhibition and apoptosis of leukemia cells possessing activating mutations of the FLT3 gene. Leuk Res 32:865-872. (Pubitemid 351389543)
23. Ozols RF, Bookman MA, du Bois A, Pfisterer J, Reuss A, and Young RC (2006) Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel. Gynecol Oncol 103:1-6. (Pubitemid 44374716)
24. Pramanik KC, Boreddy SR, and Srivastava SK (2011) Role of mitochondrial electron transport chain complexes in capsaicin mediated oxidative stress leading to apoptosis in pancreatic cancer cells. PLoS One 6:e20151.
25. Rahman KW and Sarkar FH (2005) Inhibition of nuclear translocation of nuclear factor-{kappa}B contributes to 3,3′-diindolylmethane-induced apoptosis in breast cancer cells. Cancer Res 65:364-371.
26. Rajoria S, Suriano R, Wilson YL, Schantz SP, Moscatello A, Geliebter J, and Tiwari RK (2011) 3,3′-diindolylmethane inhibits migration and invasion of human cancer cells through combined suppression of ERK and AKT pathways. Oncol Rep 25: 491-497.
27. Reed GA, Sunega JM, Sullivan DK, Gray JC, Mayo MS, Crowell JA, and Hurwitz A (2008) Single-dose pharmacokinetics and tolerability of absorption-enhanced 3,3′- diindolylmethane in healthy subjects. Cancer Epidemiol Biomarkers Prev 17: 2619-2624.
28. Rho JK, Choi YJ, Jeon BS, Choi SJ, Cheon GJ, Woo SK, Kim HR, Kim CH, Choi CM, and Lee JC (2010) Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790M mutation. Mol Cancer Ther 9:3233-3243.
29. Roux PP and Blenis J (2004) ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 68: 320-344. (Pubitemid 38756868)
30. Shi Y, Sahu RP, and Srivastava SK (2008) Triphala inhibits both in vitro and in vivo xenograft growth of pancreatic tumor cells by inducing apoptosis. BMC Cancer 8:294.
31. Sibilia M, Kroismayr R, Lichtenberger BM, Natarajan A, Hecking M, and Holcmann M (2007) The epidermal growth factor receptor: from development to tumorigenesis. Differentiation 75:770-787. (Pubitemid 350086174)
32. Steinmetz R, Wagoner HA, Zeng P, Hammond JR, Hannon TS, Meyers JL, and Pescovitz OH (2004) Mechanisms regulating the constitutive activation of the extracellular signal-regulated kinase (ERK) signaling pathway in ovarian cancer and the effect of ribonucleic acid interference for ERK1/2 on cancer cell proliferation. Mol Endocrinol 18:2570-2582. (Pubitemid 39335989)
33. Stewart JR and O'Brian CA (2004) Resveratrol antagonizes EGFR-dependent Erk1/2 activation in human androgen-independent prostate cancer cells with associated isozyme-selective PKC alpha inhibition. Invest New Drugs 22:107-117. (Pubitemid 38270466)
34. Thoennissen NH, O'Kelly J, Lu D, Iwanski GB, La DT, Abbassi S, Leiter A, Karlan B, Mehta R, and Koeffler HP (2010) Capsaicin causes cell-cycle arrest and apoptosis in ER-positive and -negative breast cancer cells by modulating the EGFR/HER-2 pathway. Oncogene 29:285-296.
35. Turner T, Chen P, Goodly LJ, and Wells A (1996) EGF receptor signaling enhances in vivo invasiveness of DU-145 human prostate carcinoma cells. Clin Exp Metastasis 14:409-418. (Pubitemid 26363215)
36. Wang Y, Kristensen GB, Helland A, Nesland JM, Børresen-Dale AL, and Holm R (2005) Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas. Am J Clin Pathol 124:392-401. (Pubitemid 41232925)
37. Wieduwilt MJ and Moasser MM (2008) The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci 65:1566-1584.
38. Yarden Y and Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137. (Pubitemid 33674041)
39. Zeineldin R, Muller CY, Stack MS, and Hudson LG (2010) Targeting the EGF receptor for ovarian cancer therapy. J Oncol 2010:414676.
40. Zhang M, Yang ZY, Binns CW, and Lee AH (2002) Diet and ovarian cancer risk: a case-control study in China. Br J Cancer 86:712-717. (Pubitemid 34250811)